Q32 Bio (QTTB) has issued an announcement.
Q32 Bio Inc. has successfully completed the enrollment phase for the SIGNAL-AD Phase 2 clinical trial of their drug bempikibart, aimed at treating persistent, moderate-to-severe atopic dermatitis. The trial explores the efficacy of bempikibart, an antibody that blocks inflammatory signaling with the hope of re-regulating immune function. With 121 patients enrolled, surpassing the initial goal due to high demand, the study’s findings are eagerly anticipated in the fourth quarter of 2024. This milestone marks a significant step for Q32 Bio Inc. as they advance in the development of potential new treatments for autoimmune disorders.
For a thorough assessment of QTTB stock, go to TipRanks’ Stock Analysis page.
